Q-omics provides the consensus-scored CHRNA6 profile across patient tissues and cancer cell-line models. CHRNA6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CHRNA6 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, CHRNA6 RNA expression shows 14,687 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where CHRNA6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHRNA6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHRNA6 survival associations across molecular data types. CHRNA6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHRNA6 RNA expression–survival associations across cancer types. High CHRNA6 expression shows unfavorable associations in UVM and LIHC, but favorable associations in HNSC, LUAD, ACC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for CHRNA6 RNA expression.
This table summarizes CHRNA6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CHRNA6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHRNA6 shows higher tumor expression in KIRC, COAD, KIRP, LUAD, HNSC and BRCA. The KIRC box plot shows higher CHRNA6 RNA expression in tumor versus normal tissue (log2 FC = +0.725, t-test p < 0.001).
This table shows molecular features associated with CHRNA6 in patient tissues and cancer cell lines. In patient samples, CHRNA6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHRNA6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and SKIN.
